Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Malaria drugs under watch: resistance study in kenya

NCT ID NCT07362498

Knowledge-focused Sponsor: Strathmore University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplicated malaria. The goal was to see if using multiple first-line treatments is practical and acceptable, and to track resistance markers in the malaria parasite.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artemether + Lumefantrine and Dihydroartemisinin-piperaquine
What this could lead to
If successful, this could help health officials choose the best combination of malaria drugs to slow down resistance and keep treatments effective longer.
What could go wrong
This is an observational study, not a test of a new cure. The findings may not apply to other regions, and drug resistance patterns can change over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

316 people

The number who actually took part.

Started

Jun 2020

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with uncomplicated Plasmodium falciparum malaria at participating government and faith-based health facilities in Homa Bay County and Migori County, Western Kenya, a malaria-endemic region with high transmission intensity.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 5 years or older * Clinical diagnosis of uncomplicated malaria * Confirmed Plasmodium falciparum infection by rapid diagnostic test (RDT) or microscopy * Presenting at participating health facility for malaria treatment * Able and willing to provide informed consent (or parental/guardian consent for minors under 18 years) * Resident of study catchment area * For molecular surveillance substudy: willingness to provide dried blood spot sample Exclusion Criteria: * Pregnant women (due to contraindications for some study medications in first trimester and lack of safety data) * Children under 5 years of age (due to lack of pediatric formulations for some study medications) * Severe or complicated malaria requiring parenteral treatment or hospitalization * Known hypersensitivity or contraindication to any of the study artemisinin-based combination therapies * Unable to take oral medications * Previous participation in current treatment episode (repeat visits) * Concurrent participation in other interventional malaria treatment studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria falciparum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria falciparum

Contacts and locations

Locations

  • Homa Bay County Health Facilities

    Homa Bay, Homa Bay County, 40300, Kenya

  • Migori County Teaching and Referral Hospital

    Migori, Migori County Kenya, 40400, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.